Decision Resources: Atrial fibrillation treatments will expand market size to $7 billion
WALTHAM, Mass. Launch and use of new heart drugs will drive the market for drugs to treat atrial fibrillation and increase its size to nearly $7 billion in less than a decade, according to a new report from market analysis firm Decision Resources.
The report found that new drugs from Boehringer Ingelheim, Sanofi-Aventis and partnerships between Bayer and Johnson & Johnson and Pfizer and Bristol-Myers Squibb –– specifically anticoagulant and antiarrhythmic drugs –– will drive most of the atrial fibrillation drug market in developed countries and increase it more than eight-fold, from $843 million in 2009 to $6.8 billion in 2019.
The drugs cited include Boehringer Ingelheim’s Pradaxa (dabigatran etexilate), Sanofi-Aventis’ Multaq (dronedarone), apixan, by Bristol and Pfizer, and Xarelto (rivaroxaban), by Bayer and J&J. These drugs are expected to drive three-quarters of the market in the United States, United Kingdom, France, Italy, Spain, Germany and Japan.
The report found that while Multaq would face challenges due to competition from another Sanofi drug, Cordarone (amiodarone), which also is available as a generic, it would likely have sales of more than $650 million in 2019.
Target gets set to open in East Harlem
MINNEAPOLIS Target announced that it will open its first store on the island of Manhattan in East Harlem on July 25.
According to the company, the store features more space devoted to fresh food, everyday essentials and home basics geared for apartment living. The store is easily accessible with a pedestrian bridge linking mass transit to the store on the second floor of the East River Plaza. A parking deck is also available.
The retailer also said it has tailored the store’s merchandise to reflect the culture of the community. As such, Target said the Harlem store will offer Spanish-language books and movies, multicultural dools and Gospel and Latin music.
As with all Target stores, the new general merchandise store will offer everyday essentials, household products, electronics, clothing and seasonal items. And, it will feature Target’s new expanded food layout offering fresh packaged produce, meats and baked goods, the company reported.
FDA approves expanded use of Infergen
WARRENDALE, Pa. The Food and Drug Administration has approved a new use for a hepatitis C drug made by Three Rivers Pharmaceuticals, the drug maker said Friday.
The FDA approved Three Rivers’ Infergen (interferon alfacon-1) combined with ribavirin for daily treatment of hepatitis C in patients who have failed to respond to pegylated interferon combined with ribavirin.
The approval is based on a late-stage clinical study showing that the combination of Infergen and ribavirin rendered the virus undetectable, also known as sustained virological response.